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Regular Article
LYMPHOID NEOPLASIA
Genetic susceptibility to radiation-induced breast cancer
after Hodgkin lymphoma
Annemieke W. J. Opstal-van Winden,1 Hugoline G. de Haan,1 Michael Hauptmann,1 Marjanka K. Schmidt,1,2 Annegien Broeks,3
Nicola S. Russell,4 Ce´cile P. M. Janus,5 Augustinus D. G. Krol,6 Frederieke H. van der Baan,1 Marie L. De Bruin,1,7 Anna M. van Eggermond,1
Joe Dennis,8 Hoda Anton-Culver,9 Christopher A. Haiman,10 Elinor J. Sawyer,11 Angela Cox,12 Peter Devilee,13,14 Maartje J. Hooning,15
Julian Peto,16 Fergus J. Couch,17 Paul Pharoah,18,19 Nick Orr,20 Douglas F. Easton,8,18 Berthe M. P. Aleman,4 Louise C. Strong,21 Smita Bhatia,22
Rosie Cooke,23 Leslie L. Robison,24 Anthony J. Swerdlow,23,25 and Flora E. van Leeuwen1
1Department of Epidemiology and Biostatistics, 2Division of Molecular Pathology, 3Division of Molecular Pathology, Core Facility Molecular Pathology and
Biobanking, and 4Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; 5Department of Radiation Oncology,
Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 6Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands;
7Copenhagen Centre for Regulatory Science (CORS), University of Copenhagen, Copenhagen, Denmark; 8Center for Cancer Genetic Epidemiology, Department
of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; 9Department of Epidemiology, University of California Irvine, Irvine, CA;
10Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA; 11Innovation Hub, Guy’s Cancer Centre, King’s
College London, London, United Kingdom; 12Sheffield Cancer Research, Department of Oncology, University of Sheffield, Sheffield, United Kingdom; 13De-
partment of Pathology and 14Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands; 15Department of Medical Oncology,
Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands; 16Department of Non-Communicable Disease Epidemiology, London School of
Hygiene and Tropical Medicine, London, United Kingdom; 17Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; 18Centre for Cancer
Genetic Epidemiology, Department of Oncology, and 19Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom;
20The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, United Kingdom; 21MD Anderson Cancer Center, Houston, TX;
22Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL; 23Division of Genetics and Epidemiology, The Institute of
Cancer Research, London, United Kingdom; 24Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital, Memphis, TN; and
25Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom
KEY PO INT S
l The risk of RT-induced
breast cancer after HL
is strongly associated
with a PRS for breast
cancer in the general
population.
l A PRS, based on 9
SNPs interacting with
RT in the occurrence of
breast cancer after
HL, also increased
RT-induced breast
cancer risk.
Female Hodgkin lymphoma (HL) patients treated with chest radiotherapy (RT) have a very
high risk of breast cancer. The contribution of genetic factors to this risk is unclear. We
therefore examined 211155 germline single-nucleotide polymorphisms (SNPs) for gene-
radiation interaction on breast cancer risk in a case-only analysis including 327 breast cancer
patients after chest RT for HL and 4671 first primary breast cancer patients. Nine SNPs
showed statistically significant interaction with RT on breast cancer risk (false discovery
rate, <20%), of which 1 SNP in the PVT1 oncogene attained the Bonferroni threshold for
statistical significance. A polygenic risk score (PRS) composed of these SNPs (RT-
interaction-PRS) and a previously published breast cancer PRS (BC-PRS) derived in the
general population were evaluated in a case-control analysis comprising the 327 chest-
irradiated HL patients with breast cancer and 491 chest-irradiated HL patients without
breast cancer. Patients in the highest tertile of the RT-interaction-PRS had a 1.6-fold higher
breast cancer risk than those in the lowest tertile. Remarkably, we observed a fourfold
increased RT-induced breast cancer risk in the highest compared with the lowest decile of
the BC-PRS. On a continuous scale, breast cancer risk increased1.4-fold per standarddeviation of theBC-PRS, similar to the
effect size found in the general population. This study demonstrates that genetic factors influence breast cancer risk after
chest RT for HL. Given the high absolute breast cancer risk in radiation-exposed women, these results can have important
implications for the management of current HL survivors and future patients. (Blood. 2019;133(10):1130-1139)
Introduction
Women who are treated at young ages with chest radiotherapy
(RT) for Hodgkin lymphoma (HL) have a 5 to 20 times increased
risk of breast cancer compared with the general population.1-11
The cumulative incidence of breast cancer up to 40 years after
treatment with mantle-field RT is 30% to 40%,5,6,10 in the range
of risks observed in BRCA1/2 mutation carriers.12 The risk of
RT-induced breast cancer rises with increasing radiation dose
and volume, but not all female HL survivors treated with high-dose,
high-volume RT develop breast cancer. Some variation in risk is
explained by age at RT exposure, which is inversely related with
breast cancer risk, and premature menopause induced by con-
comitant alkylating-chemotherapy treatment, which reduces
risk.13 However, variation in risk may also be due to genetic
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factors. The high risk of breast cancer in this population provides
an excellent opportunity to investigate the genetic basis for
differential sensitivity to radiation carcinogenesis. Although it is
well known that ionizing radiation induces DNA damage, the
molecular mechanisms underlying radiation-induced breast
carcinogenesis are unclear. To date, there is no clear evidence
that known high-risk breast cancer susceptibility genes con-
tribute to RT-induced breast cancer risk in HL patients.14-17
However, there may be a more important role for common
susceptibility variants, as suggested by genetic association studies
in women exposed to low-dose radiation, albeit with conflicting
results.18-26 The role of single-nucleotide polymorphisms (SNPs) in
breast cancer risk after therapeutic high-dose radiation has been
investigated in few studies: a small genome-wide association study
(GWAS) on any second solid malignancy in childhood HL survi-
vors27 and a GWAS on radiation-induced breast cancer in child-
hood cancer survivors.28 In addition, Ma et al investigated 14 SNPs
previously associated with breast cancer in the general population
in HL survivors.29
In the current study, we used a 2-step design to investigate
whether there are subgroups of women exposed to chest RT
who are genetically more susceptible to radiation-induced
breast cancer. We first used a case-only analysis to evaluate
interactions between 211155 SNPs and chest RT, by comparing
patients with breast cancer after chest RT for HL with first primary
breast cancer patients previously unexposed to RT. We then
conducted a nested breast cancer case-control analysis among
chest-irradiated HL survivors to evaluate a polygenic risk score
(PRS) composed of RT-interacting SNPs from the case-only
analysis (RT-interaction-PRS). As a separate aim, we studied
the effect of a previously published breast cancer PRS (BC-PRS)30
in the general population on breast cancer risk among chest-
irradiated HL survivors.
Patients and methods
Study design
When studying interaction between RT and genetic variation on
breast cancer after HL, a classical case-control study nested in
a cohort of HL survivors would not be informative because, until
recently, 90% of the patients with breast cancer after HL received
RT, resulting in too few unexposed cases. Therefore, we used
a 2-step design to identify susceptibility variants for radiation-
induced breast cancer (Figure 1). First, we examined gene-
radiation interaction for 211 155 SNPs in a case-only analysis
comparing patients with breast cancer after chest RT for HL
(further referred to as breast cancer after HL cases) and first
primary breast cancer patients (further referred to as first primary
breast cancer cases). For each SNP, we used logistic regression
analysis to estimate the per-allele interaction odds ratio (IOR),
a measure of departure from a multiplicative joint effect of the
SNP and chest RT, for the risk of breast cancer, assuming in-
dependence between chest RT and the SNP in women from the
general population.31
Second, we combined interacting SNPs in a PRS, that is, the sum
of risk alleles weighted by their effect size (see supplemental
Methods A [available on the Blood Web site] for details) and
evaluated the association between this PRS and the risk of breast
cancer after chest RT in a breast cancer case-control analysis
among irradiated HL survivors, using an independent control
group of chest-irradiated HL survivors without breast cancer as
controls (further referred to as HL controls). We similarly eval-
uated a second PRS, which was previously reported to be
associated with breast cancer in the general population (the
BC-PRS).30
Study population and genotyping
For the case-only analysis, we pooled 339 cases with breast
cancer after HL from 3 breast cancer case-control studies29,32-34
nested in HL survivor cohorts: the Childhood Cancer Survivor
study (CCSS),35 a British HL cohort,10 and the Dutch Hodgkin
Lymphoma Cohort.6 Blood samples from these cases were
genotyped using a custom Illumina iSelect Array comprising
211155 SNPs, specially designed for the European Collabora-
tive Oncological Gene-Environment Study (EU-COGS) project
(referred to as iCOGS array).36 Extensive patient and HL treat-
ment characteristics, as well as follow-up data, were available
from medical records,4,29,35 through questionnaires sent to
general practitioners and study participants, and from record
linkages with national cancer registries.6,10,14,29,32-34 Female
patients with breast cancer after HL were included in our study if
they were diagnosed with primary breast cancer .8 years after
chest RT for HL before the age of 41 years (see supplemental
Methods B for definition of chest RT). Cases with breast cancer
after HL were frequency matched (1:;14) on age and year of
breast cancer diagnosis (5-year intervals) and country, to 4673
first primary breast cancer cases of European origin not known
to be exposed to chest RT. These were selected from 19275
participants of 10 studies from The Netherlands, United King-
dom, and the United States within the Breast Cancer Association
Consortium (BCAC)36 for whom iCOGS genotype data were
available. When there were too few subjects in a specific age
category, we oversampled in an adjacent age category in the
same calendar year category.
For the case-control analysis, we included the 339 cases
with breast cancer after HL mentioned previously and 508 HL
– Test 194,106 SNPs for statistical interaction with RT among:
 – Calculate Polygenic Risk Score (risk-weighted sum) of:
      • SNPs significantly interacting with RT (RT-interaction-PRS)
      • 77 SNPs associated with BC in general population* (BC-PRS)
      – Test association of both PRSs with BC after HL among:
      – Obtain IOR (Interaction Odds Ratio) per SNP
      – Select most significant SNPs for validation in 2nd step
RT for HL BC
327 BC after HL cases
BC
4671 1st primary BC cases
year & age
RT for HL
RT for HL
BC
327 BC after HL cases
No BC
491 HL controls
year & age
A
B
Figure 1. Study design. (A) First step: case-only study. (B) Second step: case-control
study. IOR, interaction odds ratio. *See Mavaddat et al.30
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Table 1. Population characteristics of the breast cancer after HL cases, first primary breast cancer cases, andHL controls
without breast cancer
Breast cancer after HL
cases, N 5 327
First primary breast cancer
cases, N 5 4671
HL controls without breast
cancer, N 5 491
Age at breast cancer diagnosis, y
Median (range) 45 (24-76) 46 (22-84) NA
20-29 8 (2.4) 96 (2.1) NA
30-39 88 (26.9) 855 (18.3) NA
40-49 139 (42.5) 2224 (47.6) NA
50-59 68 (20.8) 1129 (24.2) NA
60-69 20 (6.1) 314 (6.7) NA
701 4 (1.2) 53 (1.1) NA
Year of breast cancer diagnosis*
Median (range) 2003 (1984-2013) 2000 (1964-2011) NA
,1990 12 (3.7) 226 (4.8) NA
1990-1994 25 (7.6) 606 (13.0) NA
1995-1999 72 (22.0) 1377 (29.5) NA
2000-2004 86 (26.3) 1329 (28.5) NA
2005-2009 99 (30.3) 1067 (22.8) NA
2010-2014 33 (10.1) 66 (1.4) NA
Age at HL diagnosis, y
Median (range) 19 (10-40) NA 22 (6-40)
,15 40 (12.2) NA 36 (7.3)
15-19 134 (41.0) NA 140 (28.5)
20-24 76 (23.2) NA 140 (28.5)
25-29 38 (11.6) NA 76 (15.5)
30-34 31 (9.5) NA 85 (17.3)
35-40 8 (2.4) NA 14 (2.9)
Year of HL diagnosis†
1965-1973 92 (28.1) NA 119 (24.2)
1974-1979 120 (36.7) NA 132 (26.9)
1980-1984 60 (18.3) NA 109 (22.2)
1985-1999 55 (16.8) NA 131 (26.7)
Interval between HL and breast
cancer diagnosis (cases) or end
of follow-up (controls), y
Median (range) 24 (9-46) NA 30 (9-49)
9-,15 28 (8.6) NA 6 (1.2)
$15-,25 144 (44.0) NA 113 (23.0)
$25-,35 127 (38.8) NA 238 (48.5)
$35 28 (8.6) NA 134 (27.3)
HL treatment‡
RT only 160 (48.9) NA 201 (40.9)
RT and chemotherapy 160 (48.9) NA 284 (57.8)
RT; chemotherapy missing 7 (2.1) NA 6 (1.2)
Data are n (%) unless otherwise noted.
NA, not applicable.
*Four cases with breast cancer after HL had missing year of breast cancer diagnosis, which were imputed with the median year of breast cancer diagnosis among participants from the same
country.
†Four cases with breast cancer after HL and 6 HL controls had missing year of HL diagnosis. These missing years were imputed with the median year of HL diagnosis among participants in the
same group (cases or controls) from the same country.
‡For the Dutch HL survivors, chest RT was defined as (in)complete mantle field or mediastinal RT, or RT to the lungs or axilla. Subjects with only infradiaphragmatic RT were excluded. For HL
survivors from the United States, chest RT was defined as chest or total nodal RT (subjects with only brain, other head, neck, abdomen, spine, pelvis, and/or limb RT were excluded). For HL
survivors from the United Kingdom, chest RT was defined as mantle field, chest, mediastinal, axillary, mini mantle field or partial chest RT (subjects with only neck, clavicular and/or head or
other supradiaphragmatic RT or infradiaphragmatic RT, RT field unknown or chemotherapy only were excluded).
§Information on the radiation fields was only available for HL survivors from the United Kingdom and The Netherlands.
||Pelvic RT encompassed RT to the whole abdomen or iliac nodes on both sides, or RT with inverted Y field, in women with no (successful) oophoropexy.
¶Alkylating chemotherapy consists of combinations of cytostatic agents with at least 1 alkylating agent (ie, procarbazine, cyclophosphamide, ifosfamide, lomustine, melphalan, dacarbazine,
cisplatin, mechlorethamine, chlorambucil, and carmustine).
1132 blood® 7 MARCH 2019 | VOLUME 133, NUMBER 10 OPSTAL-van WINDEN et al
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/133/10/1130/1556879/blood862607.pdf by guest on 08 June 2020
survivors treated with chest RT who did not develop breast
cancer until end of follow-up, available from the 3 breast cancer
case-control studies described earlier in this section. For all HL
controls without breast cancer, we collected similar data as
described earlier in this section for cases with breast cancer after
HL. In the published original case-control studies,13,32-34 which
examined radiation dose-response, 1 to 4 controls were in-
dividually matched to each case. Controls had to have survived
without breast cancer at least as long as the interval between HL
and breast cancer for the corresponding case, and in case of the
US study, had to have donated a blood sample. In addition,
controls had tomatch the case on age at HL treatment (63 years)
and date of HL treatment (65 years). Controls from the original
case-control studies were excluded if they were not treated with
chest RT, were treated at or after age 41 years, and/or did not
donate a blood sample. In addition, controls were excluded if
they developed breast cancer after the year of breast cancer
diagnosis of the case to whom they had been matched. For the
current study, we added recently diagnosed breast cancer
after HL cases fulfilling the inclusion criteria. All separate studies
involved in this collaboration were approved by the relevant
institutional review boards, and all individuals gave written in-
formed consent.
Quality control on genotype data
After quality control, 194 106 SNPs measured in 4671 first pri-
mary breast cancer cases, 327 cases with breast cancer after HL,
and 491 HL controls without breast cancer remained for anal-
yses. See supplemental Methods C for details on quality control.
Statistical analyses
In the case-only analysis, comparing breast cancer after HL
cases and first primary breast cancer cases, we estimated the
per-allele IOR by unconditional logistic regression analysis for
all variants passing quality control, adjusting for the matching
factors (age and year of breast cancer diagnosis, both con-
tinuous, and country) and the first principal component de-
scribing remaining genetic ethnic differences among European
subjects (referred to as ethnicity) (see supplemental Methods
D). P values for the IORs were calculated by the score test
Table 1. (continued)
Breast cancer after HL
cases, N 5 327
First primary breast cancer
cases, N 5 4671
HL controls without breast
cancer, N 5 491
Mantle-field irradiation§
Yes 234 (90.7) NA 371 (84.9)
No 18 (7.0) NA 60 (13.7)
Missing 6 (2.3) NA 6 (1.4)
Pelvic RT||
Yes 39 (11.9) NA 59 (12.0)
No 288 (88.1) NA 432 (88.0)
Alkylating chemotherapy¶
Yes 133 (40.7) NA 253 (51.5)
No 176 (53.8) NA 211 (43.0)
Missing 18 (5.5) NA 27 (5.5)
Gonadotoxic treatment
Alkylating chemotherapy and/or
pelvic RT
152 (46.5) NA 278 (56.6)
No alkylating chemotherapy and no
pelvic RT
158 (48.3) NA 192 (39.1)
Missing 17 (5.2) NA 21 (4.3)
Country
The Netherlands 112 (34.3) 1646 (35.2) 168 (34.2)
United Kingdom 146 (44.6) 2380 (51.0) 269 (54.8)
United States 69 (21.1) 645 (13.8) 54 (11.0)
Data are n (%) unless otherwise noted.
NA, not applicable.
*Four cases with breast cancer after HL had missing year of breast cancer diagnosis, which were imputed with the median year of breast cancer diagnosis among participants from the same
country.
†Four cases with breast cancer after HL and 6 HL controls had missing year of HL diagnosis. These missing years were imputed with the median year of HL diagnosis among participants in the
same group (cases or controls) from the same country.
‡For the Dutch HL survivors, chest RT was defined as (in)complete mantle field or mediastinal RT, or RT to the lungs or axilla. Subjects with only infradiaphragmatic RT were excluded. For HL
survivors from the United States, chest RT was defined as chest or total nodal RT (subjects with only brain, other head, neck, abdomen, spine, pelvis, and/or limb RT were excluded). For HL
survivors from the United Kingdom, chest RT was defined as mantle field, chest, mediastinal, axillary, mini mantle field or partial chest RT (subjects with only neck, clavicular and/or head or
other supradiaphragmatic RT or infradiaphragmatic RT, RT field unknown or chemotherapy only were excluded).
§Information on the radiation fields was only available for HL survivors from the United Kingdom and The Netherlands.
||Pelvic RT encompassed RT to the whole abdomen or iliac nodes on both sides, or RT with inverted Y field, in women with no (successful) oophoropexy.
¶Alkylating chemotherapy consists of combinations of cytostatic agents with at least 1 alkylating agent (ie, procarbazine, cyclophosphamide, ifosfamide, lomustine, melphalan, dacarbazine,
cisplatin, mechlorethamine, chlorambucil, and carmustine).
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performed using the GenABEL package within R (see sup-
plemental Methods E). Based on a conservative Bonferroni
correction, SNPs with a P value , 2.6E-07 were considered
statistically significant. Furthermore, we applied the false dis-
covery rate (FDR) by Benjamini and Hochberg37 to identify
SNPs among which the expected proportion of false positives is
,20% (q value 5 0.2). For significant SNPs in linkage dis-
equilibrium (LD; r2 . 0.7), only the SNP with the lowest P value
was included in the PRS.
Subsequently, for all subjects in the case-control analysis
(breast cancer after HL cases and HL controls), we calculated
the RT-interaction-PRS consisting of SNPs interacting with RT
on breast cancer at 20% FDR and the 77 SNP BC-PRS. Missing
genotypes were imputed by the mode among HL controls.
Odds ratios (ORs) and corresponding 95% confidence intervals
(CIs) for RT-induced breast cancer after HL were calculated by
unconditional logistic regression per standard deviation (SD)
increase in either the RT-interaction-PRS and/or the BC-PRS,
adjusted for each other and for age at HL diagnosis (continu-
ous), year of HL diagnosis (4 periods), country, and ethnicity.
We also calculated ORs for breast cancer by categories of the
PRSs (tertiles for the RT-interaction-PRS and deciles for the
BC-PRS). P values for the ORs were based on Wald tests.
Interaction between the RT-interaction-PRS and gonadotoxic
treatment of HL (yes/no) and between the RT-interaction-PRS
and age at HL treatment (#20/.20 years) was tested by
stratification on these factors. As a sensitivity analysis, we
assessed the association of a PRS including only the SNPs
attaining the Bonferroni threshold for statistical significance.
For all Bonferroni-significant SNPs in the case-only analysis, we
also tested their individual association with breast cancer after
chest RT in the case-control analysis using logistic regression
adjusted for age at and year of HL diagnosis, country, and
ethnicity. All analyses were conducted with R software (www.r-
project.org).
Data availability
Nonidentifiable data that support the findings of this study will
be made available upon reasonable request. Access to the
BCAC data are governed by the Data Access Coordinating
Committee from BCAC. Data from the CCSS study can be re-
trieved from dbGAP using accession number phs001327.v1.p1.
Results
Study populations of the case-only and
case-control analysis
We included 327 breast cancer after HL cases from cohorts of
female HL patients in The Netherlands, United Kingdom, and
United States and 4671 frequency-matched first primary breast
cancer cases previously unexposed to RT from the same
countries in the case-only analysis. Furthermore, we included
491 HL controls in the case-control analysis (see Table 1 for the
numbers of subjects by country). The median age at breast
cancer diagnosis was 45 years (range, 24-76 years) for breast
cancer after HL cases and 46 years (range, 22-84 years) for age-
matched first primary breast cancer cases (Table 1). The median
interval between HL and breast cancer diagnosis was 24 years
(range, 9-46 years). For HL controls, median follow-up was
30 years (range, 9-49 years). Most HL cases and controls (87%)
were treated with mantle-field irradiation, whereas 11% of the
HL cases and controls receivedmediastinal radiotherapy without
axillary node radiotherapy. Approximately one-half of the breast
cancer after HL cases and almost 60% of HL controls were
treated for HL with chemotherapy in addition to RT. Approxi-
mately 45% of breast cancer after HL cases and 57% of HL
controls received gonadotoxic treatment (ie, alkylating che-
motherapy and/or pelvic RT).
SNPs interacting with RT on breast cancer risk
(case-only analysis)
We tested 194106 SNPs that passed quality control for an in-
teraction with chest RT in the case-only analysis of breast cancer
patients (QQ plot is depicted in supplemental Figure 1). As shown
in Table 2, 3 SNPs were statistically significantly associated at the
Bonferroni threshold for multiple testing (P , 2.6E-07) and 7 ad-
ditional SNPs met the 20% FDR threshold, of which 1 SNP was
excludedbecause of strong LD (r25 0.9). The estimated per-allele
IORs for these 9 SNPs ranged from 1.6 to 2.2. Most SNPs were
quite common in the breast cancer after HL cases with minor
allele frequencies (MAFs) between 2.8% and 43.7%.
PRS for RT-induced breast cancer
(case-control analysis)
We constructed an RT-interaction-PRS of the 9 SNPs that
showed a statistically significant (FDR, 20%) interaction with RT-
induced breast cancer. The RT-interaction-PRS increased breast
cancer risk after chest RT for HL with ORs of 1.2 (95% CI, 0.8-1.7;
P5 .348) and 1.6 (95%CI, 1.1-2.4; P5 .007), respectively, for the
middle and highest tertiles compared with the lowest tertile,
adjusted for age and year of HL diagnosis, country, ethnicity, and
the BC-PRS (Figure 2; supplemental Table 1). TheOR per 1 SD of
the RT-interaction-PRS was 1.3 (95% CI, 1.1-1.5; P 5 .002).
Additional adjustment for gonadotoxic treatment did not affect
the association of the RT-interaction-PRS with breast cancer
risk (ORadjusted, 1.3; 95% CI, 1.1-1.5), suggesting that it is unlikely
that chemotherapy has confounded our analyses. In addition,
stratified analyses resulted in similar associations between the
RT-interaction-PRS and breast cancer risk among women who
received gonadotoxic treatment (alkylating chemotherapy
and/or pelvic RT) and women who did not; we observed no
statistically significant interaction between the RT-interaction-
PRS and gonadotoxic treatment (P5 .337; supplemental Table 1).
Likewise, stratification by ageat HL treatment (#20,.20 years) did
not result in different associations between the RT-interaction-PRS
and breast cancer risk after RT for HL; there was no interaction
between age at HL treatment and the RT-interaction PRS
(P 5 .954).
In a sensitivity analysis, we observed that a PRS containing only
the 3 SNPs reaching the Bonferroni threshold for statistical sig-
nificance also increased breast cancer risk withORs of 1.4 (95%CI,
1.0-2.1; P5 .070) and 1.6 (95%CI, 1.1-2.2; P5 .018), respectively,
for themiddle and highest tertile compared with the lowest tertile
which consisted of noncarriers. The OR per 1 SD of the 3 SNP RT-
interaction-PRS was 1.2 (95% CI, 1.0-1.4; P 5 .014).
To confirm the observed associations, we also evaluated
the individual effects of the 3 Bonferroni-significant SNPs on
RT-induced breast cancer in the case-control analysis among
chest-irradiated HL survivors (supplemental Table 2). Of these,
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an intronic variant in oncogene PVT1 (rs10505506) was asso-
ciated with RT-induced breast cancer risk after HL with an OR of
1.3 (95% CI, 1.1-1.6; P 5 .007) per allele copy. Of note,
rs10505506 is not in LD (r2 , 0.3 in Europeans from the 1000
Genomes Project38) with previously identified cancer risk var-
iants in the PVT1 locus (supplemental Figure 2).
PRS based on known breast cancer SNPs
(case-control analysis)
To evaluate the combined effect of known breast cancer SNPs,
we studied a BC-PRS containing 76 SNPs that increase breast
cancer risk in the general population30 in chest-irradiated HL
survivors. The BC-PRS was associated with a 1.4-fold increased
risk of RT-induced breast cancer (95% CI, 1.2-1.6; P 5 9.1E-05)
per SD increase in the BC-PRS. The ORs for developing breast
cancer after chest RT for HL by deciles of the BC-PRS, com-
pared with women in the middle quintile (40th to 60th per-
centile), are shown in Figure 3 and supplemental Table 3. The
10% of women with the lowest BC-PRS had an OR of 0.6 (95%
CI, 0.3-1.1; P 5 .133) for developing RT-induced breast cancer
compared with women in the middle quintile, whereas the OR
for the 10% of women with the highest BC-PRS was 2.4 (95% CI,
1.4-4.2; P 5 .002), adjusted for age and year of HL diagnosis,
country, ethnicity, and the RT-interaction-PRS (in tertiles). This
results in a fourfold relative risk for the 10% of women with the
highest compared with the lowest BC-PRS. There was no interac-
tion between the RT-interaction-PRS and the BC-PRS (P 5 .645).
Discussion
This study demonstrates that genetic factors influence the risk of
breast cancer after chest RT for HL. We showed that a BC-PRS,
consisting of 77 SNPs previously associated with breast cancer
in the general population, also substantially increases the risk
of breast cancer in chest-irradiated HL survivors. In addition, we
identified 9 SNPs interacting with chest RT and the risk of breast
cancer after HL and we showed a statistically significant as-
sociation of a PRS composed of these interaction SNPs with
breast cancer risk after chest RT for HL using an independent
control group. These results imply that the absolute risk of
breast cancer due to irradiation would be (even) larger among
women at high genetic risk, which is relevant for clinical risk
prediction.
Importantly, we validated the previously published BC-PRS in
a high-risk population of female chest-irradiated HL survivors
and found that there are large differences in risk between
women with a low and high PRS. More specifically, we observed
a fourfold increased relative risk between chest-irradiated HL
survivors in the highest compared with the lowest decile of the
BC-PRS. On a continuous scale, the effect size was very similar to
that found in the general population (OR of 1.4 per SD in our
study of HL survivors compared with ORs of 1.4 to 1.6 per SD
in the general population).30,39 These results indicate that the
effects of radiation exposure and common susceptibility variants,
summarized in the PRS, combine approximately multiplicatively.
Given the high absolute breast cancer risk in radiation-exposed
women, these results have important implications for their
management. The BC-PRS can be used to help guide treatment
decisions in newly diagnosed HL patients as well as to help
determine breast surveillance strategies for irradiated HL survi-
vors. Annual breast cancer surveillance between the ages of
25 and 50 years is currently recommended by the International
Late Effects of Childhood Cancer Guideline Harmonization
Group for female survivors of childhood, adolescent, and
young adult cancer who received $20 Gy chest radiation
before age 30 years.40 Less clear is the evidence for surveillance
in women treated at older ages, with lower dosages, or with
Table 2. Characteristics of SNPs statistically significantly (20% FDR) interacting with RT in the case-only analysis
SNP Locus Chr Position* Alleles
Breast cancer
after HL cases,
N 5 327
First primary
breast cancer
cases, N 5 4671
Statistical interaction
with chest RT on
breast cancer risk†
Weight RT-
interaction-
PRS
MAF N called MAF N called IOR 95%CI P‡ Log IOR
rs10505506 PVT1 8 129114473 G/C 0.407 327 0.306 4670 1.6 1.3-1.8 3.1E-08 0.44
rs12086369 1p31.1 1 79644149 G/A 0.073 324 0.035 4667 2.1 1.5-2.8 9.4E-08 0.74
rs9461776 HLA 6 32683713 A/G 0.133 327 0.079 4671 1.8 1.4-2.3 1.1E-07 0.59
MitoA7769G MT 7769 A/G 0.052 325 0.020 4653 2.1 1.5-3.0 2.8E-06 0.76
rs1017639 CPT1A 11 68355110 A/C 0.073 327 0.043 4669 1.9 1.4-2.6 2.8E-06 0.63
MitoT9900C MT 9900 A/G 0.028 325 0.011 4669 2.0 1.3-3.2 3.7E-06 0.71
MitoA13781G MT 13781 A/G 0.036 306 0.011 4592 2.2 1.5-3.3 4.3E-06 0.80
rs2296008 COL19A1 6 70935424 G/A 0.041 327 0.020 4669 2.2 1.4-3.4 6.8E-06 0.79
rs3815871 PVT1 8 129077760 G/C 0.437 327 0.341 4671 1.5 1.3-1.8 8.5E-06 0.40
Chr, chromosome; CI, confidence interval; FDR, false discovery rate; IOR, interaction odds ratio; MAF, minor allele frequency; MT, mitochondrial DNA.
*Positions are based on NCBI36/hg18.
†Logistic regression analysis per SNP to test the log additive effect per allele (per-allele IOR) with adjustment for age at and year of breast cancer diagnosis, country, and ethnicity.
‡All listed SNPs were significant at a 20% FDR. Top 3 SNPs were statistically significant at the Bonferroni threshold (P , 2.6E-07).
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different radiation volumes. Therefore, clinical prediction models
for breast cancer that include both clinical and genetic factors can
help to identify (additional) women who may benefit from breast
cancer surveillance.
We chose to evaluate the 77 SNP BC-PRS by Mavaddat et al30 as
this PRS has been associated with breast cancer risk in the
general population and in high-risk groups such as BRCA1 and
BRCA2 mutation carriers,39,41 allowing direct comparison of
the reported effect sizes. Nevertheless, many more common
susceptibility variants have recently been identified for breast
cancer in the general population.42,43 Addition of these SNPs to
the BC-PRS may further improve risk stratification for breast
cancer in chest-irradiated HL survivors and in other high-risk
groups. Inclusion of SNPs associated with hormone receptor-
negative breast cancer may be of particular interest, as several
studies have reported that HL survivors are more likely to de-
velop hormone receptor-negative disease.44-46
We applied an innovative design to examine the role of SNP-
radiation interactions in breast cancer risk after HL. This is not
feasible in a classical breast cancer case-control study in HL
0.0
0.5
1.0
Breast cancer after
Hodgkin lymphoma
cases, n(%)
Hodgkin lymphoma
controls without
breast cancer, n(%)
Low Medium
9-SNP RT-interaction-PRS
High
94 (28.7) 105 (32.1) 128 (39.1)
168 (34.2) 176 (35.8) 147 (29.9)
1.5
2.0
2.5
OR
 (9
5%
 C
I)
3.0
3.5
4.0
P for trend = 0.002
P = 0.348
P = 0.007
Figure 2. Risk of breast cancer after chest RT by tertiles
of the RT-interaction-PRS among HL survivors.
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I)
3.0
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Figure 3. Risk of breast cancer after chest RT by deciles
of the BC-PRS in the breast cancer after HL case-control
analysis.
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survivors, as, until recently, ;90% of breast cancer cases after
HL received chest RT. Therefore, we first performed a case-only
analysis in breast cancer patients previously exposed and un-
exposed to chest RT, followed by a case-control analysis in HL
survivors to evaluate the combined effect of the identified
RT-interaction SNPs in a PRS. We used a 20% FDR as a cutoff to
select SNPs interacting with RT for the RT-interaction-PRS, as it
has been shown that the performance of a PRS improves when
using more liberal thresholds than the conservative Bonferroni
threshold.47,48 Although a PRS consisting of 3 SNPs statistically
significant at the Bonferroni threshold showed a similar associ-
ation with RT-induced breast cancer risk among HL survivors, the
goodness of fit was better in the full PRS (data not shown).
The IORs that we estimated in the case-only analysis measure
departure from a multiplicative joint effect of chest RT and the
SNP, assuming independence between chest RT and the SNP in
women from the general population.49 This assumption is likely
to be justified except for SNPs associated with HL. SNPs asso-
ciated with HLmay also have shown a significant IOR in the case-
only analysis. On the other hand, such SNPs may be associated
with both HL and (radiation-induced) breast cancer and,
therefore, we did not exclude SNPs previously associated with
HL from inclusion in the RT-interaction-PRS. If they were only
associated with HL they would have attenuated the association
of the RT-interaction-PRS with breast cancer after chest RT in the
case-control analysis. In the case-only analysis, we identified 1
SNP (rs9461776) interacting with radiation at 20% FDR sig-
nificance located in the HLA region, which has extensively been
reported to be associated with HL.50 rs9461776 showed no
evidence of an association with breast cancer after chest RT
(OR, 1.0; 95% CI, 0.8-1.4; P . .5) in the case-control analysis in
HL survivors and may therefore have attenuated the associa-
tion of the RT-interaction-PRS with the risk of breast cancer after
chest RT.
Of the 9 SNPs (MAF . 1%) interacting with RT on breast cancer
risk at 20% FDR, 1 attained the genome-wide level (P, 53 1028)
of statistical significance. This SNP (rs10505506) was also as-
sociated with breast cancer risk in chest-irradiated HL survivors
(OR, 1.3; 95% CI, 1.1-1.6; P 5 .007). SNP rs10505506 is located
in the intronic region of PVT1, which is a known oncogene
regulated by tumor-suppressor p53 encoding a long noncoding
RNA and several microRNAs.51,52 PVT1 has been shown to interact
with the adjacent proto-oncogeneMYC and translocations in this
locus have been associated with Burkitt lymphoma. In addition,
overexpression of PVT1 is associated with several types of cancers
including breast cancer, acute myeloid leukemia, and HL. Like-
wise, GWAS studies have identified several conditionally in-
dependent SNPs in this locus associated with cancer, including
breast cancer and HL,53,54 but none of these are in LD with
rs10505506. A potential link with radiation has recently been
suggested in a mouse model after whole-body irradiation.55
The association of the RT-interaction-PRS with breast cancer risk
after HL was not weakened in “low-risk” groups of women ir-
radiated at older age (ie, 20 years or older) or women treated
with gonadotoxic treatment. In addition, we did not observe
interaction between the RT-interaction-PRS and either gonadotoxic
treatment or age at HL treatment. This is in line with the notion
that gonadotoxic treatment and age at HL treatment are in-
dependent risk factors for breast cancer risk after HL. This suggests
that age and treatment-related risk factors for breast cancer after
HL and the genetic risk scores (both the RT-interaction-PRS
and the BC-PRS) combinemultiplicatively as has previously been
shown for several reproductive risk factors and the 77 SNP BC-
PRS in the general population.56
A limitation of this study is that the study populations for the
construction and evaluation of the RT-interaction-PRS were not
independent, as the breast cancer after HL cases were included
in both analyses. External validation of the RT-interaction-PRS
in an independent study is therefore needed to confirm our
findings. In addition, we excluded SNPs with a low MAF (,1%)
from our analyses, as these low-frequency SNPs are more prone
to genotyping errors. However, Morton et al recently reported
2 suggestive associations for low-frequency variants at 11q23
and 1q32.3, both not present on the iCOGS array, with breast
cancer risk after childhood cancer,28 suggesting a potential role
for low-frequency SNPs in RT-induced breast cancer. Inclusion
of these SNPs to the RT-interaction-PRS might strengthen its
association with RT-induced breast cancer. Likewise, additional
SNPs interacting with RT on breast cancer may be identified
when assessing SNP data from denser genotyping chips im-
puted to a reference panel. However, in this first analysis,
we focused on high-quality SNPs specifically selected for the
iCOGS array.
In conclusion, we showed that a BC-PRS previously developed
in the general population also applies in a high-risk breast cancer
population of chest-irradiated HL survivors. In addition, we
developed an RT-interaction-PRS composed of 9 SNPs inter-
acting with radiation that was associated with raised breast
cancer risk after chest RT for HL. Although our RT-interaction-
PRS needs validation in an independent sample, the BC-PRS can
already be applied in clinical practice. This can benefit treatment
decision-making in future HL patients as well as identification of
high-risk survivors eligible for breast cancer surveillance.
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